Several other research analysts have also recently issued reports on GNS. Peel Hunt reaffirmed a buy rating and issued a GBX 2,600 ($35.26) price target on shares of Genus in a report on Monday, October 9th. N+1 Singer raised Genus to a buy rating and upped their price target for the company from GBX 1,844 ($25.01) to GBX 2,485 ($33.70) in a report on Monday, October 30th. Finally, Kepler Capital Markets started coverage on Genus in a report on Tuesday, November 7th. They issued a hold rating and a GBX 2,353 ($31.91) price target on the stock. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Genus presently has an average rating of Hold and an average target price of GBX 2,270.60 ($30.79).
Genus (LON:GNS) traded down GBX 6 ($0.08) during midday trading on Monday, hitting GBX 2,518 ($34.15). The company’s stock had a trading volume of 31,444 shares, compared to its average volume of 47,446. The company has a market capitalization of $1,580.00 and a PE ratio of 4,750.94. Genus has a 52 week low of GBX 1,652 ($22.40) and a 52 week high of GBX 2,597 ($35.22).
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/16/genus-gns-earns-hold-rating-from-liberum-capital.html.
Genus Company Profile
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company’s segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe.
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.